ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY
M MohtyaM TomassonbB ArnulfcN BahlisdM PrinceeR NiesvizkyfP Rodrgue-OterogJ Martine-LopezhG KoehneiY JethavajA GabayankD StevenslA NookamN RajenS IidaoE LeippU ConteqA CzibereqA ViqueirarV BlunksA Lesokhint
a Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France
b Holden Comprehensive Cancer Center, University of Iowa, Iowa City, United States
c Hôpital Saint-Louis, Paris, France
d Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
e Epworth Healthcare, Melbourne, Australia
f Weill Cornell Medical College – New York Presbyterian Hospital, New York, United States
g Clinica Universidad de Navarra, Madrid, Spain
h Hospital Universitario 12 DE OCTUBRE, Madrid, Spain
i Miami Cancer Institute, Miami, United States
j Indiana Blood & Marrow Transplant, Indianapolis, United States
k Beverly Hills Cancer Center, Beverly Hills, United States
l Norton Cancer Center, Louisville, United States
m Winship Cancer Institute, Atlanta, United States
n Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States
o Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
p Pfizer Inc, Cambridge, United States
q Pfizer Inc, New York, United States
r Pfizer SLU, Madrid, Spain
s Pfizer, São Paulo, Brazil
t Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States
Ver másRead
235
Timeswas read the article
120
Total PDF
115
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 May | 26 | 19 | 45 |
| 2024 April | 42 | 16 | 58 |
| 2024 March | 15 | 9 | 24 |
| 2024 February | 10 | 13 | 23 |
| 2024 January | 5 | 9 | 14 |
| 2023 December | 6 | 17 | 23 |
| 2023 November | 10 | 24 | 34 |
| 2023 October | 1 | 13 | 14 |
